May 19, 2016
Intratumoral Administration of INT230-6 Improves Drug Diffusion and Uptake into Cancer Cells in Patients with Advanced Solid Tumors
Emerging Therapies, Web Exclusives
Coming soon…Related Articles
TLR9 Agonist plus Immunotherapy May Overcome Resistance to PD-1 Inhibition
According to data from a preliminary phase 1b clinical trial, a novel approach using the investigational toll-like receptor 9 (TLR-9) agonist CMP-001 in combination with pembrolizumab may have the potential to reverse resistance to anti–PD-1 therapy.
March 08, 2019 – FDA Approvals, News & Updates
Approvals for new delivery methods for Herceptin and Cinvanti, and a new indication for Lonsurf close out the month of February in the FDA’s oncology-related activity.